Last reviewed · How we verify

NCT05048381

miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis (TB)

Withdrawn Last updated 1 November 2023
What this trial tests

trial testing Next Generation Sequencing in Active Tuberculosis. Withdrawn.

Timeline
6 September 2021
Primary endpoint
31 October 2022
31 October 2022

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
StatusWithdrawn
Study typeOBSERVATIONAL
Start date6 September 2021
Primary completion31 October 2022
Estimated completion31 October 2022

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Active Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The detection of miRNA (non-coding ribonucleic acid) in the blood in the context of active tuberculosis is an innovative approach to the detection of new disease-specific biomarkers. The primary goal of this analysis is to define, for the first time, an miRNA fingerprint for tuberculosis in sweat. Samples that were collected as part of the Sweatb Study (NCT03667742) project are examined for the occurrence of disease-specific, non-coding miRNAs to define new biomarkers in the sweat. These biomarkers can be detected non-invasively and will help in the detection of patients with active tuberculosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Next Generation Sequencing

Trials testing the same drug.

Other recruiting trials for Active Tuberculosis

Currently open trials in the same condition.

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05048381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing